ImmunityBio (IBRX) Non-Current Debt (2020 - 2025)
Historic Non-Current Debt for ImmunityBio (IBRX) over the last 6 years, with Q3 2025 value amounting to $316.1 million.
- ImmunityBio's Non-Current Debt rose 1552.6% to $316.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $316.1 million, marking a year-over-year increase of 1552.6%. This contributed to the annual value of $284.4 million for FY2024, which is 8299.65% up from last year.
- As of Q3 2025, ImmunityBio's Non-Current Debt stood at $316.1 million, which was up 1552.6% from $307.0 million recorded in Q2 2025.
- ImmunityBio's 5-year Non-Current Debt high stood at $480.0 million for Q3 2023, and its period low was $155.4 million during Q4 2023.
- In the last 5 years, ImmunityBio's Non-Current Debt had a median value of $300.3 million in 2021 and averaged $293.4 million.
- Data for ImmunityBio's Non-Current Debt shows a peak YoY increase of 8299.65% (in 2024) and a maximum YoY decrease of 4299.05% (in 2024) over the last 5 years.
- ImmunityBio's Non-Current Debt (Quarter) stood at $306.3 million in 2021, then rose by 21.85% to $373.3 million in 2022, then crashed by 58.37% to $155.4 million in 2023, then soared by 83.0% to $284.4 million in 2024, then increased by 11.16% to $316.1 million in 2025.
- Its Non-Current Debt stands at $316.1 million for Q3 2025, versus $307.0 million for Q2 2025 and $296.3 million for Q1 2025.